Galderma Group Ltd Canada (GALD.SW) shared on Monday that Health Canada has given the green light to NEMLUVIO, which is the first biologic treatment specifically for moderate-to-severe atopic dermatitis and prurigo nodularis.
This approval is for patients who are 12 and older dealing with atopic dermatitis, as well as adults with prurigo nodularis who haven't found relief with topical prescriptions.
NEMLUVIO is also notable for being the first monoclonal antibody targeting the IL-31 receptor alpha approved in Canada for these conditions. The endorsement is backed by encouraging phase III trial results from ARCADIA and OLYMPIA, which showed quick and significant improvements in itchiness, skin lesions, and sleep issues.
GALD.SW closed trading on Monday at CHF 163.90 down CHF 1.30 or 0.79 percent on the Six Swiss Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.